JP2010511701A - 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法 - Google Patents
水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法 Download PDFInfo
- Publication number
- JP2010511701A JP2010511701A JP2009540237A JP2009540237A JP2010511701A JP 2010511701 A JP2010511701 A JP 2010511701A JP 2009540237 A JP2009540237 A JP 2009540237A JP 2009540237 A JP2009540237 A JP 2009540237A JP 2010511701 A JP2010511701 A JP 2010511701A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ischemic
- formula
- treatment
- corresponds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010010904 Convulsion Diseases 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 33
- RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical class C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000000144 pharmacologic effect Effects 0.000 title claims abstract description 10
- 230000002490 cerebral effect Effects 0.000 title description 6
- 230000001154 acute effect Effects 0.000 title description 4
- 230000004087 circulation Effects 0.000 title description 3
- 208000030090 Acute Disease Diseases 0.000 title 1
- 208000017667 Chronic Disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 117
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims description 56
- 230000000694 effects Effects 0.000 claims description 25
- 208000006011 Stroke Diseases 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000000573 anti-seizure effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000008196 pharmacological composition Substances 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract description 47
- 230000002008 hemorrhagic effect Effects 0.000 abstract description 30
- 241001465754 Metazoa Species 0.000 description 41
- 241000700159 Rattus Species 0.000 description 41
- 208000032382 Ischaemic stroke Diseases 0.000 description 31
- 239000000203 mixture Substances 0.000 description 29
- 239000003814 drug Substances 0.000 description 27
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 26
- 238000002560 therapeutic procedure Methods 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 22
- 238000002648 combination therapy Methods 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 238000009472 formulation Methods 0.000 description 17
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 16
- 210000004556 brain Anatomy 0.000 description 16
- 230000034994 death Effects 0.000 description 16
- 231100000517 death Toxicity 0.000 description 16
- 229960000715 nimodipine Drugs 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 238000001356 surgical procedure Methods 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 201000001119 neuropathy Diseases 0.000 description 10
- 230000007823 neuropathy Effects 0.000 description 10
- 208000033808 peripheral neuropathy Diseases 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- 206010033799 Paralysis Diseases 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 208000010877 cognitive disease Diseases 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 7
- 208000028698 Cognitive impairment Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001715 carotid artery Anatomy 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000003678 AMPA Receptors Human genes 0.000 description 4
- 108090000078 AMPA Receptors Proteins 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- -1 dimebon include Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- JIHMATXQZDSUOR-UHFFFAOYSA-N 2,3,4,4a,5,5a-hexahydro-1h-pyrido[4,3-b]indole Chemical compound N1C2C=CC=CC2=C2C1CCNC2 JIHMATXQZDSUOR-UHFFFAOYSA-N 0.000 description 3
- CYJQCYXRNNCURD-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2C1CCN(C)C2 CYJQCYXRNNCURD-UHFFFAOYSA-N 0.000 description 3
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 description 3
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RPROHCOBMVQVIV-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCNC2 RPROHCOBMVQVIV-UHFFFAOYSA-N 0.000 description 2
- IKMNOGHPKNFPTK-UHFFFAOYSA-N 2-ethyl-6-methylpyridin-1-ium-3-ol;4-hydroxy-4-oxobutanoate Chemical compound OC(=O)CCC(O)=O.CCC1=NC(C)=CC=C1O IKMNOGHPKNFPTK-UHFFFAOYSA-N 0.000 description 2
- ANRUJJLGVODXIK-UHFFFAOYSA-N 3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide Chemical compound NCCC(=O)NCCC1=CN=CN1 ANRUJJLGVODXIK-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- CJUOSBUQOWKEKJ-UHFFFAOYSA-N Mebhydrolin napadisilate Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 CJUOSBUQOWKEKJ-UHFFFAOYSA-N 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002253 anti-ischaemic effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 108700021352 carcinine Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical class IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 230000009251 neurologic dysfunction Effects 0.000 description 2
- 208000015015 neurological dysfunction Diseases 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 229960003642 nicergoline Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- CYJQCYXRNNCURD-DGCLKSJQSA-N (4ar,9bs)-2,8-dimethyl-1,3,4,4a,5,9b-hexahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2[C@@H]2[C@H]1CCN(C)C2 CYJQCYXRNNCURD-DGCLKSJQSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- BPPMRCNUQCVVFJ-UHFFFAOYSA-N 2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical class N1C2=CC=CC=C2C2C1CCNC2 BPPMRCNUQCVVFJ-UHFFFAOYSA-N 0.000 description 1
- MUZFLDUALLSEBH-UHFFFAOYSA-N 2,8-dimethyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(C)C=C2C2=C1CCN(C)C2 MUZFLDUALLSEBH-UHFFFAOYSA-N 0.000 description 1
- XWLFAMANDIWUKH-UHFFFAOYSA-N 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole-2,5-diium;dichloride Chemical compound Cl.Cl.N1C2=CC=C(C)C=C2C2C1CCN(C)C2 XWLFAMANDIWUKH-UHFFFAOYSA-N 0.000 description 1
- TWZCZLLZJDKWFN-UHFFFAOYSA-N 2-benzyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound C1CC=2NC3=CC=CC=C3C=2CN1CC1=CC=CC=C1 TWZCZLLZJDKWFN-UHFFFAOYSA-N 0.000 description 1
- FYHWPFXPFFPQRT-UHFFFAOYSA-N 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CCN(C)C2 FYHWPFXPFFPQRT-UHFFFAOYSA-N 0.000 description 1
- UPLUVROGBHSYKI-UHFFFAOYSA-N 2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CCC1=CC=C(C)N=C1 UPLUVROGBHSYKI-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NGNVOGPUTBVHTL-UHFFFAOYSA-N 5-benzyl-2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1=CC=CC=C1 NGNVOGPUTBVHTL-UHFFFAOYSA-N 0.000 description 1
- PPRXPSDHSSUMRZ-UHFFFAOYSA-N 5-benzyl-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 PPRXPSDHSSUMRZ-UHFFFAOYSA-N 0.000 description 1
- HFILMDDJKHXWEL-UHFFFAOYSA-N 8-bromo-2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole Chemical compound N1C2=CC=C(Br)C=C2C2=C1CCN(C)C2 HFILMDDJKHXWEL-UHFFFAOYSA-N 0.000 description 1
- XGGILFZLGXIRFW-UHFFFAOYSA-N 8-chloro-2-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 XGGILFZLGXIRFW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- JYIJLCGEBZRACV-UHFFFAOYSA-N Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 Chemical compound Cl.Cl.C1NCCC=2NC=3C=CC=CC3C21 JYIJLCGEBZRACV-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229940127505 Sodium Channel Antagonists Drugs 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044522 Traumatic haematoma Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229950010754 dicarbine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940125384 geroprotector Drugs 0.000 description 1
- RZXHTPCHKSYGIB-UHFFFAOYSA-N gevotroline Chemical compound C1C=2C3=CC(F)=CC=C3NC=2CCN1CCCC1=CC=CN=C1 RZXHTPCHKSYGIB-UHFFFAOYSA-N 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 1
- 229960004934 mebhydrolin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2006143332/15A RU2340342C2 (ru) | 2006-12-07 | 2006-12-07 | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| PCT/US2007/024626 WO2008073231A1 (en) | 2006-12-07 | 2007-11-30 | Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4, 3-b) indoles (variants), pharmacological means based thereon and method for the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511701A true JP2010511701A (ja) | 2010-04-15 |
| JP2010511701A5 JP2010511701A5 (enExample) | 2011-01-20 |
Family
ID=39512028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540237A Pending JP2010511701A (ja) | 2006-12-07 | 2007-11-30 | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110112132A1 (enExample) |
| EP (1) | EP2101578A4 (enExample) |
| JP (1) | JP2010511701A (enExample) |
| AU (1) | AU2007332878A1 (enExample) |
| CA (1) | CA2671569A1 (enExample) |
| RU (1) | RU2340342C2 (enExample) |
| WO (1) | WO2008073231A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090221627A1 (en) | 2007-09-20 | 2009-09-03 | Alexey Aksinenko | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009120720A1 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies,Inc. | Bridged heterocyclic compounds and methods of use |
| CN104387382A (zh) | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
| AU2009308708B2 (en) | 2008-10-31 | 2015-11-19 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| US8907097B2 (en) | 2008-10-31 | 2014-12-09 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| RU2011137419A (ru) | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| EP2424364A4 (en) | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
| EP2424366B1 (en) | 2009-04-29 | 2016-02-17 | Medivation Technologies, Inc. | Pyrido [4, 3-b]indoles and methods of use |
| US8859561B2 (en) | 2009-09-23 | 2014-10-14 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| JP5869484B2 (ja) | 2009-09-23 | 2016-02-24 | メディベイション テクノロジーズ， インコーポレイテッド | 架橋複素環化合物およびその使用 |
| WO2011038163A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| WO2012112961A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
| US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| BR112013021126A2 (pt) | 2011-02-18 | 2019-09-24 | Medivation Technologies Inc | método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica |
| US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| RU2477131C1 (ru) * | 2012-01-17 | 2013-03-10 | Алиса Владимировна Алесенко | СРЕДСТВО ДЛЯ НЕЙТРАЛИЗАЦИИ ТОКСИЧЕСКОГО ДЕЙСТВИЯ ФАКТОРА НЕКРОЗА ОПУХОЛИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ, ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ НА ОСНОВЕ НЕЙТРАЛИЗАЦИИ ТОКСИЧЕСКОГО ДЕЙСТВИЯ ФАКТОРА НЕКРОЗА ОПУХОЛИ |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187785B1 (en) * | 1995-10-23 | 2001-02-13 | Selena Pharmaceuticals, Inc. | Agent for treating neurodegenerative disorders |
| WO2005055951A2 (en) * | 2003-12-08 | 2005-06-23 | Medivation, Inc. | Methods and compositions for slowing aging |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08507514A (ja) * | 1993-03-08 | 1996-08-13 | 藤沢薬品工業株式会社 | 脳血管性疾患を治療または予防するための薬物 |
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
-
2006
- 2006-12-07 RU RU2006143332/15A patent/RU2340342C2/ru not_active IP Right Cessation
-
2007
- 2007-11-30 CA CA002671569A patent/CA2671569A1/en not_active Abandoned
- 2007-11-30 WO PCT/US2007/024626 patent/WO2008073231A1/en not_active Ceased
- 2007-11-30 EP EP07867589A patent/EP2101578A4/en not_active Withdrawn
- 2007-11-30 AU AU2007332878A patent/AU2007332878A1/en not_active Abandoned
- 2007-11-30 JP JP2009540237A patent/JP2010511701A/ja active Pending
- 2007-11-30 US US12/518,090 patent/US20110112132A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187785B1 (en) * | 1995-10-23 | 2001-02-13 | Selena Pharmaceuticals, Inc. | Agent for treating neurodegenerative disorders |
| WO2005055951A2 (en) * | 2003-12-08 | 2005-06-23 | Medivation, Inc. | Methods and compositions for slowing aging |
Non-Patent Citations (5)
| Title |
|---|
| JPN6013000681; ＳＴＯＬＥ， Ｓ． ｅｔ ａｌ．: Ｃｅｌｌｕｌａｒ ａｎｄ Ｍｏｌｅｃｕｌａｒ Ｎｅｕｒｏｂｉｏｌｏｇｙ Ｖｏｌ．２６，Ｎｏ．７／８, 200610, ｐ．１４９５-１５０４ * |
| JPN6013000682; ＢＡＣＨＵＲＩＮ， Ｓ． ｅｔ ａｌ．: Ａｎｎａｌｓ Ｎｅｗ Ｙｏｒｋ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ Ｖｏｌ．９３９， Ｎｏ．１, 200601, ｐ．４２５-４３５ * |
| JPN6013000683; ＳＵＮ， Ａ． ｅｔ ａｌ．: Ｃｌｉｎｉｃａｌ Ｎｅｕｒｏｐｈａｒｍａｃｏｌｏｇｙ Ｖｏｌ．２２， Ｎｏ．３, 1999, ｐ．１６４-１７１ * |
| JPN6013000684; ＲＹＡＮ， Ｍ． ｅｔ ａｌ．: Ｐｈａｒｍａｃｏｔｈｅｒａｐｙ Ｖｏｌ．１７， Ｎｏ．５, 1997, ｐ．９５９-９６９ * |
| JPN6013000685; ＬＥＥＳ， Ｋ．Ｒ．: Ｂｒ． Ｊ． Ｃｌｉｎ． Ｐｈａｒｍａｃ． Ｖｏｌ．３４, 1992, ｐ．４８６-４９３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006143332A (ru) | 2008-06-20 |
| CA2671569A1 (en) | 2008-06-19 |
| RU2340342C2 (ru) | 2008-12-10 |
| EP2101578A1 (en) | 2009-09-23 |
| EP2101578A4 (en) | 2012-09-05 |
| WO2008073231A1 (en) | 2008-06-19 |
| AU2007332878A1 (en) | 2008-06-19 |
| US20110112132A1 (en) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110112132A1 (en) | Means for the treatment of acute and chronic disorders of cerebral circulation, including insult, based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof | |
| JP2010511616A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法 | |
| CA2599937A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders | |
| NZ518901A (en) | A levetiracetam alone or in combination with a compound inducing neural inhibition mediated by the GABA receptors for treatment of chronic pain, bipolar disorder, mania and migraine | |
| JP2012505257A (ja) | 多発性硬化症治療のための組成物および方法 | |
| US20200121704A1 (en) | Methods for treating hypertension and arterial stiffness | |
| US20070249562A1 (en) | Treatment of atrial fibrillation | |
| US20240016790A1 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| CN108463224A (zh) | sGC刺激剂用于胃肠功能障碍治疗的应用 | |
| CA2899602A1 (en) | Pharmaceutical uses of inorganic nitrites | |
| US20020077355A1 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
| TW201313679A (zh) | 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途 | |
| JP2006096665A (ja) | 脊柱管狭窄症治療剤 | |
| TW202308653A (zh) | 以神經活性類固醇進行治療的方法 | |
| EP3556366A1 (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| US11666643B1 (en) | Micronutrient combination to reduce blood pressure | |
| CA2695822A1 (en) | A combination treatment | |
| JP2003535897A (ja) | アンギオテンシンｉｉアンタゴニストの新規使用法 | |
| JP2025504447A (ja) | アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療 | |
| JPWO2017022787A1 (ja) | 収縮力低下随伴性排尿筋過活動改善剤 | |
| EP2184284B1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient | |
| JP2004051639A (ja) | 動脈硬化症治療のための医薬組成物 | |
| JP4677705B2 (ja) | 頭痛の予防および／または治療剤 | |
| KR20080089279A (ko) | 우울증의 예방 및/또는 치료제 | |
| JP2004505919A (ja) | 一次性頭痛の処置におけるビタミン配合物の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130325 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131115 |